ICH Q6Specifications: Test Procedures and Acceptance Criteria

ICH Q6 is actually two related guidelines: Q6A (Step 4, October 1999) covers chemical substances — small molecules — and Q6B (Step 4, March 1999) covers biotechnological and biological products. Both define the universal set of tests and the structure of a release specification that a manufacturer commits to in the regulatory filing and that the manufacturer (and any contracted lab) must execute on every batch before release.

Although the guidelines are mature (1999), they remain the operative reference because Q6 is the foundation for every CTD Module 3.2.S.4 (drug substance specification) and 3.2.P.5 (drug product specification) section. The 25-year-old text is supplemented by Q3A/B/C/D on impurities, Q4B on pharmacopoeial harmonisation, and Q14 on the analytical-procedure lifecycle.

Q6A §3.3 then layers on specific tests that apply when relevant: physicochemical properties (pH, solubility, polymorphism), particle size, water content (USP <921>), microbial limits, sterility (for sterile substances), bacterial endotoxins, and chiral identity / chiral purity for stereoisomers. Every test must reference a validated analytical procedure and a numerical acceptance criterion derived from manufacturing experience plus a safety/efficacy justification.

For the drug product Q6A §3.4 specifies: description, identification, assay, impurities (degradation products only — process impurities are controlled at the substance level), uniformity of dosage units (USP <905>), and microbial limits. Specific dosage forms add their own tests: tablets and capsules need dissolution (USP <711>) and disintegration; parenterals need sterility, endotoxins, particulate matter, fill volume; topical formulations need preservative content and antimicrobial effectiveness if preserved.

Q6A is explicit that release acceptance criteria can be tighter than shelf-life acceptance criteria when degradation during the shelf life is well-characterised. A common pattern: release assay 95.0–105.0 %, shelf-life assay 90.0–110.0 %, with the gap reserved for ICH Q1 stability degradation.

Q6B handles proteins, peptides, monoclonal antibodies, recombinant products, vaccines, and other biotechnological/biological products. The chemical-substance frame breaks down because biologicals are characterised by their process — heterogeneity is the rule, not the exception — so Q6B adds: characterisation (primary, secondary, tertiary, quaternary structure), physicochemical properties (isoelectric point, glycosylation profile, charge variants), biological activity (potency assay, expressed as IU or specific activity), immunochemical properties (antigenicity, binding), and purity (host-cell protein, host-cell DNA, leached protein-A for mAbs, aggregates, fragments).

Two structural Q6B requirements differ from Q6A. First, the reference standard is foundational — every biotech assay reports activity relative to a qualified reference standard, and the reference-standard programme must itself be specified and controlled. Second, the manufacturing process is part of the specification in a way it is not for small molecules — significant process changes can trigger comparability studies under ICH Q5E even when the chemical specification still passes.

Q6A §2.5 sets the rule for how acceptance criteria are derived: from the data supporting the regulatory filing (development batches, registration batches, stability data, clinical batches), with a safety and efficacy justification. The criteria must be tight enough to ensure quality but wide enough to cover normal manufacturing variability — a specification set at the mean ± 1 SD of three registration batches will fail under normal operation by chance.

The practical workflow: take all relevant historical data, calculate the observed range, set the acceptance criterion at or just outside that range with statistical justification (typically ±3 SD or a tolerance interval), and confirm the criterion is clinically meaningful. ICH Q9(R1) quality risk management informs how tight is tight enough.

Q6A allows reduced testing under specific conditions: periodic or skip testing for tests where the result is consistently well within acceptance criteria and where the test is not stability-indicating (e.g. residual solvents that are consistently below ICH Q3C limits, particle size for a granulation that has demonstrated lot-to-lot consistency). The reduction must be justified statistically and the periodic frequency defined in the specification.

Sites often misapply this: skip testing is not 'we'll test when we feel like it'. It is a defined frequency (e.g. every 10th batch, every quarter) with a rolling re-establishment trigger if any periodic test fails. The reduced testing programme must itself be approved as part of the registered specification.

1. Release specification tighter than filed — sites apply an internal limit but report against the filed limit, creating a paper-only deviation when the internal limit is exceeded.
2. Identification by a single method — Q6A §3.3.1 requires an orthogonal second method for new drug substances.
3. Impurity limits set at the LOQ of the method rather than the qualification threshold in Q3A — under-reporting impurities present above the qualification threshold.
4. Dissolution acceptance criteria copied from a USP monograph without justification that the formulation behaves identically.
5. Skip testing applied without a defined frequency or without the trigger-back-to-routine rule documented.
6. Reference standard expiry expired — every assay since expiry technically invalid.
7. Specification changed without filing — even tightening a limit can require a notification or supplement.
8. Stability specification identical to release specification — no allowance for stability degradation creates inevitable shelf-life OOS.

• Specifications are first-class objects in V5 LIMS with separate release and shelf-life acceptance criteria, periodic-test frequency, and a derivation-justification audit trail.
• Every method on a specification line carries its Q2(R2) validation reference and the LOQ-vs-acceptance-criterion check is built in.
• Reference-standard programme is enforced — expired standards block the assay sequence at the instrument.
• Skip-testing programmes are configured per analyte with the trigger-back-to-routine rule (OOT, OOS, change-control event) automated.
• Specification changes go through change control, generate a new specification version, and reports rendered after the change reference the new version.
• Annual Product Quality Review pulls every release result against its specification and trends out-of-trend signals.